A61K 2239/54
Pancreas
A61K2239/54 (Pancreas) appears on 110 US grants and 296 published applications in this corpus.
Search patents in A61K- Granted patents
- 110
- Published applications
- 296
- Assignees
- 160
- Inventors
- 555
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 1 | 5 |
| 2008 | 4 | 0 |
| 2009 | 1 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 3 |
| 2012 | 0 | 4 |
| 2013 | 2 | 4 |
| 2014 | 0 | 3 |
| 2015 | 2 | 3 |
| 2016 | 3 | 6 |
| 2017 | 2 | 11 |
| 2018 | 5 | 10 |
| 2019 | 4 | 14 |
| 2020 | 6 | 30 |
| 2021 | 8 | 28 |
| 2022 | 10 | 33 |
| 2023 | 16 | 40 |
| 2024 | 16 | 40 |
| 2025 | 14 | 32 |
| 2026 | 11 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Polypeptide specific for mucin 1 and use thereof23 Jun 2026US 12,661,402 B2LG Chem.Ltd.
- T-cell immunotherapy specific for WT-116 Jun 2026US 12,653,886 B2Fred Hutchinson Cancer Center
- Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy12 May 2026US 12,624,081 B2The Trustees of the University of Pennsylvania
- Tumor specific antibody conjugates and uses therefor21 Apr 2026US 12,605,469 B2OncoTAb, Inc.
- Modified gamma delta t cells20 Aug 2026US 2026/0242730 A1Pointloma Biosciences, Inc.
- Therapeutic T-Cell Receptors Targeting KRAS G12D13 Aug 2026US 2026/0232734 A1
- Recombinant immune cell-based cell therapeutic agent for treating cancer via polyclonal expansion of tumor-infiltrating t cell in tumor6 Aug 2026US 2026/0224615 A1Korea Advanced Institute of Science and Technology
- Cancer-killing cells23 Jul 2026US 2026/0207663 A2LIfT BioSciences Ltd
- Anti-5t4 antibody-natural killer cell conjugate and use thereof23 Jul 2026US 2026/0207746 A1Imbioray (Hangzhou) Biomedicine Co., Ltd.
Most cited
By later US patents
- Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer87US 9,233,125 B2University of Maryland, Baltimore · 2016
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Tissue targeted antigenic activation of the immune response to treat cancers17US 9,320,787 B2Qu Biologics Inc. · 2016
- Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy13US 7,175,839 B1Meyer Pharmaceuticals LLC · 2007
- Tissue targeted antigenic activation of the immune response to treat cancers13US 9,107,864 B2Qu Biologics Inc. · 2015